Esomeprazole Magnesium Introduction

Esomeprazole magnesium is a proton pump inhibitor (PPI) and the S-isomer of omeprazole (levorotatory form). Its magnesium salt formulation (chemical formula: C₁₇H₁₈N₃O₃S·Mg) offers enhanced stability and higher bioavailability.

Mechanism of Action

It irreversibly inhibits the H⁺/K⁺-ATPase (proton pump) in gastric parietal cells, significantly suppressing gastric acid secretion with greater efficacy than omeprazole:

• Reduces gastric pH, alleviating acid-related symptoms.

• Promotes mucosal healing in gastroesophageal reflux disease (GERD).

• Used in combination therapy to eradicate Helicobacter pylori (Hp).

Esomeprazole Magnesium Specification

Appearance	white powder
Melting Point	>169℃
Content	98.0%
Storage Condition	2-8℃
Packaging	50mg

Esomeprazole Magnesium Applications

Esomeprazole Magnesium is mainly used in the treatment of gastric ulcer, duodenal ulcer, and reflux esophagitis caused by excessive gastric acid secretion.

Side Effects

Type	Symptoms	Notes
Common	Headache, diarrhea, nausea, bloating	Usually transient, resolves after discontinuation
Long-term risks	Hypomagnesemia, osteoporosis, vitamin B₁₂ deficiency	Requires monitoring, especially in elderly patients
Rare	Interstitial nephritis, C. difficile infection	Discontinue immediately and seek medical care

Esomeprazole vs. Omeprazole

Omeprazole, the first proton pump inhibitor (PPI), was introduced in Switzerland in 1988 and belongs to the first generation of PPIs. Esomeprazole, introduced in the UK in 2000, is a second-generation PPI.

Chemically, omeprazole exists as a racemic combination of both the R- and S- optical isomers, whereas esomeprazole is the purified S-isomer obtained after removing the less active R-isomer from omeprazole. This refinement results in considerably enhanced acid suppression activity.

Comparative clinical trials on esomeprazole and omeprazole in gastric ulcer treatment have confirmed that esomeprazole has an overall effective rate of 93.24%, significantly higher than that of 73.61% for omeprazole, yet with no statistically significant difference between rates of adverse reactions.